Study Watch with Irregular Pulse Monitor

by Verily Life Sciences  · Based in United States →Building the future of precision health.
Cardiology Family Medicine Internal Medicine

Contact for pricing
Regulatory Status Disclosed

Overview

The Verily Study Watch with Irregular Pulse Monitor is a sophisticated, miniaturized physiological data monitoring device developed by Verily Life Sciences. It is specifically indicated for use by adult patients (22 years and older) who have been diagnosed with, or are susceptible to developing, atrial fibrillation. The device enables these patients to monitor and record their heart rhythms, and is also designed to record, store, transfer, and display single-channel electrocardiogram (ECG) rhythms. A key feature is its ability to notify the user in the event of an irregular pulse, such as atrial fibrillation (AF), and recommend the acquisition of an ECG for further assessment. While cleared for use in professional healthcare facility environments and as a prescription-only device, the Study Watch also serves as a crucial tool in clinical research, capturing a wide array of biometric, environmental, and movement data for studies across various therapeutic areas, including cardiovascular health, Parkinson’s disease, and heart failure.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Single-channel ECG recording, storage, transfer, and display
  • Irregular pulse monitoring and notification (e.g., for Atrial Fibrillation)
  • Recommendation for ECG acquisition upon irregular pulse detection
  • Built-in biometric, environmental, and movement sensors
  • Continuous data capture with long battery life (e.g., 3-day for related Numetric Watch)
  • Designed for clinical research and investigational use
  • Easy-to-use interface and configurable firmware
  • Supports multiple languages
  • Remote data collection capabilities

Use Cases

  • Monitoring adult patients (22+) with diagnosed or suspected atrial fibrillation
  • Clinical research studies (e.g., Project Baseline, Aurora study, Parkinson's, Heart Failure)
  • Screening, diagnosis, and management of atrial fibrillation
  • Investigating digital biomarkers for various conditions (cardiovascular, CNS, metabolic, respiratory, oncology)
  • Real-world evidence generation
  • Longitudinal studies to understand health and disease progression

What Physicians Need to Know

Arrhythmia Detection Accuracy
The Study Watch with Irregular Pulse Monitor has received 510(k) clearance for detecting irregular pulse, specifically for atrial fibrillation (AFib). It continuously monitors heart rhythm using photoplethysmography (PPG) and employs a unique deep neural network algorithm, trained on real-world data, to accurately detect AFib. If AFib is suspected via PPG, the user is prompted to take a single-lead ECG for confirmation. Clinical studies have confirmed its accuracy in detecting AFib episodes, showing comparable performance to other PPG-based AFib-detecting smartwatches. The device maintained comparable accuracy during low and moderate activity levels, though a slight decrease was observed for some AFib episodes in participants with darker skin tones, it still detected AFib in those patients.
Cardiac Monitoring Integration
ECG measurements are securely transferred from the watch to Verily's cloud server using a charging dock (Cradle) and Verily's Study Hub device, accessible to HCPs through a web portal. Verily is actively exploring technical integrations with iRhythm's Zio Service to enhance continuous monitoring, data analytics, and cloud-based machine learning for AFib management. The Verily Numetric Watch, a related investigational device, supports remote and continuous data capture for research. Recent collaborations, such as with Samsung, aim to integrate sensor data from consumer wearables like the Galaxy Watch into Verily's precision health platform, Pre, for research purposes.
Real-Time Alert Capability
When the photoplethysmography (PPG) sensor suspects atrial fibrillation, the wearer is prompted by the device to record a single-lead ECG for confirmation. The patient does not have direct access to the collected ECG waveform on the watch. The results are then analyzed by a cardiographic technician before being reported to the participant's physician. In a related collaboration, the Samsung Galaxy Watch, integrated with Verily's platform, features an 'Irregular Heart Rhythm Notification Feature' that analyzes pulse rate data to identify irregular rhythms suggestive of AFib and provides a notification to the user to record an ECG.
Physician Tip

The Verily Study Watch with Irregular Pulse Monitor serves as a valuable tool for continuous, prescription-based monitoring of patients at risk for or diagnosed with atrial fibrillation. Physicians should note that while the watch provides real-time prompts for ECG capture upon suspected irregular rhythms, the definitive analysis and interpretation of ECG waveforms are performed by a cardiographic technician and then made available to the HCP via a secure web portal. This workflow supports clinical decision-making by providing objective data for review. The device's accuracy in AFib detection, even during activity, makes it suitable for long-term surveillance in a real-world setting. Consider its use for patients requiring ongoing AFib monitoring where traditional intermittent methods may miss paroxysmal events.

The Verily Study Watch ecosystem facilitates data transfer to a secure cloud platform for HCP review. Future integrations with services like iRhythm's Zio aim to enhance data analytics and machine learning capabilities for AFib. The broader Verily platform, including Numetric Watch and collaborations with consumer wearables like the Samsung Galaxy Watch, highlights a strategic direction towards integrating diverse sensor data for comprehensive health monitoring and research, offering potential for more holistic patient insights in cardiovascular care.

Details

Category Cardiology AI, Wearables & Remote Monitoring (RPM)
Pricing Contact for pricing
  • Prescription-only device for clinical research and healthcare facility use; contact Verily for details
DeploymentDevice-based (wrist-worn watch)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status True AI-estimated

The Study Watch with Irregular Pulse Monitor received 510(k) clearance (K192415 on January 17, 2020) as a Class II medical device for its irregular pulse monitor feature. It is indicated for adult patients (22 years and older) diagnosed with or susceptible to atrial fibrillation to monitor and record heart rhythms and display single-channel ECGs. It is a prescription-only device. An expanded indication (K213357 on July 19, 2022) includes home use and interoperability with the ZEUS System.

Integrations
EHR Not specified
Specialties Cardiology, Family Medicine, Internal Medicine

What the Web Says

The Verily Study Watch with Irregular Pulse Monitor is a prescription-only, wrist-worn device designed for clinical research and healthcare settings to detect irregular heart rhythms, specifically atrial fibrillation (AFib). It has received FDA 510(k) clearance for its irregular pulse monitor and ECG features. The watch utilizes photoplethysmography (PPG) to monitor heart rhythm and, if an irregular pulse is suspected, prompts the user to take a single-lead ECG for confirmation, with results reviewed by a cardiographic technician before being sent to a physician. The device is intended for adult patients (22 years and older) who have been diagnosed with or are susceptible to developing AFib.

Overall: Positive

Strengths

  • FDA-cleared for irregular pulse monitoring and ECG, indicating a high level of accuracy and reliability for medical use.
  • Designed for clinical-grade data collection, supporting robust research and clinical care.
  • Accurate at identifying atrial fibrillation, with a study showing correct identification in the vast majority of participants.
  • Offers continuous monitoring of heart rhythm.
  • Integrates with healthcare providers through a cloud-based data network (as the Zio Watch).
  • Long battery life due to simpler software and e-paper technology compared to consumer smartwatches.

Limitations

  • Not directly available to consumers; it is a prescription-only device for clinical and professional healthcare use.
  • Performance may decrease for some AFib episodes in participants with darker skin tones, though still able to detect AFib.
  • Consumer-grade smartwatches, while popular, can lead to false positives for AFib, causing unnecessary testing and anxiety.
  • Wrist-based optical sensors in general can have a high false positive rate and be affected by movement, poor skin contact, or sensor limitations.
  • Some consumer smartwatches have limitations in detecting arrhythmias other than AFib or providing documentation-grade ECG data.
  • Accuracy of wrist-based heart rate monitors can be affected by factors like temperature and sweat, and may not be as accurate as chest straps for exercise.

Based on reviews from: Verily moves further into heart research as Study Watch picks up new FDA clearance, Clinical smart watch finds success at identifying atrial fibrillation | Michigan Medicine, Verily Study Watch AFib clearance, NCT06041373 | Verily Watch Cardio (AF and ECG) Study | ClinicalTrials.gov, Verily's heart-tracking wearable evolves into the Zio Watch via iRhythm partnership, new FDA clearances - Fierce Biotech, Alphabet's Verily health watch gets limited ECG clearance from FDA - CNET, Verily Study Watch Irregular Heartbeat Detection Clears FDA - SlashGear, July 19, 2022 Verily Life Sciences LLC Dinesh Puppala Regulatory Affairs Specialist 269 East Grand Avenue South San Francisco, C - accessdata.fda.gov, health monitor watch flagging irregular rhythm, sensor error or worth worrying about? : r/HealthTech - Reddit, Physician Responses to Apple Watch-Detected Irregular Rhythm Alerts - PMC - NIH, Verily nets irregular pulse clearance for its clinical study smartwatch | Fierce Biotech, Smartwatches and Atrial Fibrillation: What Works and What Needs Improvement?, Performance of the Verily Study Watch for measuring sleep compared to polysomnography, Consumer-grade wearable cardiac monitors: What they do well, and what needs work, Wrist heart rate monitors on smart watches are not as accurate as a chest strap - Reddit, What's the best smart watch for monitoring heart rythm? : r/AFIB - Reddit, Want to monitor heart irregularities. Should I buy smartwatch? - Mayo Clinic Connect, Comparison of diagnostic accuracy of electrocardiogram-based versus photoplethysmography-based smartwatches for atrial fibrillation detection: A Systematic Review and Meta-Analysis, Best Heart Monitors of 2026: Physician-Tested Accuracy Rankings

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Study Watch with Irregular Pulse Monitor

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Verily Blog
Verily Study Watch AFib clearance
Verily announced receiving a new 510(k) clearance from the FDA for its Study Watch with Irregular Pulse Monitor, validating its approach to building clinical-grade tools for cardiovascular care. The device is indicated for adults 22 and older susceptible to atrial fibrillation, enabling monitoring and recording of heart rhythms.
2020-01
Becker's Hospital Review
Verily receives FDA clearance for arrhythmia monitoring wearable - Becker's Hospital Review | Healthcare News & Analysis
Alphabet's life sciences subsidiary Verily was granted 510(k) clearance from the FDA on Jan. 17, 2020, for a feature enabling irregular pulse detection by its Study Watch wearable device. This clearance expands the device's capabilities beyond its initial clearance for on-demand electrocardiograms.
2020-01
Healthcare Dive
FDA approves Verily's Study Watch to monitor cardiovascular conditions
Verily Life Sciences received FDA 510(k) clearance for its Study Watch with Irregular Pulse Monitor, allowing it to monitor patients over 22 years old susceptible to atrial fibrillation. The device can record, store, transfer, and display single-channel ECG rhythms.
2020-01
FierceBiotech
Verily moves further into heart research as Study Watch picks up new FDA clearance
Verily, Alphabet's life sciences research arm, received FDA 510(k) clearance for its Study Watch to include an irregular pulse monitor feature. This new capability will be leveraged to develop solutions for screening, diagnosis, and management of atrial fibrillation, including a collaboration with iRhythm.
2020-01
Medical Design & Outsourcing
Verily gets second Study Watch FDA clearance as it digs into Irhythm AF collaboration
Verily received a second FDA clearance for its Study Watch as an irregular pulse monitor, building on its initial clearance for on-demand ECGs. This clearance is expected to be useful in conjunction with iRhythm's Zio wearable monitor for AF detection and management.
2020-01
GlobeNewswire
iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System
iRhythm Technologies received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) system for the Zio Watch, which is the Study Watch with Irregular Pulse Monitor. This integrated, prescription-based solution detects and characterizes AFib using a continuous PPG, AI-based algorithm.
2022-07
Cardiac Rhythm News
iRhythm's ZEUS system gains US FDA approval - Cardiac Rhythm News
iRhythm Technologies secured FDA 510(k) clearance for its ZEUS system for the Zio Watch, developed in partnership with Verily. The Zio Watch, also cleared by the FDA, is a wrist-worn solution for long-term continuous monitoring of atrial fibrillation.
2022-07
FDA
510(k) Premarket Notification for Study Watch with Irregular Pulse Monitor
This FDA 510(k) summary details the Study Watch with Irregular Pulse Monitor, indicated for adults 22 and older susceptible to atrial fibrillation for monitoring and recording heart rhythms. It also records, stores, transfers, and displays single-channel ECG rhythms.
2020-01

Videos

Product demos, reviews, and walkthroughs for Study Watch with Irregular Pulse Monitor.

Loading videos...

View all on YouTube

Frequently Asked Questions

The AI algorithm is trained on extensive ECG datasets to identify specific patterns indicative of conditions like atrial fibrillation. Its accuracy is typically validated against gold-standard ECG readings in clinical studies, providing sensitivity and specificity metrics for its performance. For instance, the iRhythm ZEUS system for the Zio Watch, which uses an AI-based algorithm, showed interval-level sensitivity and specificity of 93.6% and 99.1% respectively in detecting AF.
The Study Watch and its AI irregular pulse monitor typically receive regulatory clearances such as FDA 510(k) clearance as a medical device. This ensures it meets established safety and effectiveness standards for its intended use in detecting irregular heart rhythms. For example, the Verily Study Watch (Zio Watch) with iRhythm's AI algorithm (ZEUS) received FDA 510(k) clearance for detecting atrial fibrillation.
The device employs robust encryption protocols for data at rest and in transit, adhering to HIPAA guidelines for protected health information. AI processing occurs within a secure, compliant environment, and data is anonymized or de-identified where appropriate for algorithm improvement. Healthcare organizations must ensure any AI technology they use is HIPAA-compliant, including proper data handling practices, secure infrastructure, and Business Associate Agreements where required.
While traditional Holter monitors provide continuous, high-fidelity ECG data for a limited period, AI-powered watches offer long-term, continuous monitoring for intermittent events. They serve as a screening tool, potentially identifying events that might be missed by shorter-duration monitoring, though often requiring confirmation with a clinical-grade ECG. Studies have shown smartwatches can significantly improve the detection rate of atrial fibrillation compared to conventional monitoring.
The cost typically includes an upfront purchase price for the device and a recurring subscription fee for the AI monitoring service and data access. Reimbursement varies by payer and region, but medical-grade wearables may be eligible for coverage, and CPT codes for remote physiological monitoring or extended ECG monitoring may apply, requiring proper documentation for billing.
The AI algorithm may have limitations in distinguishing certain benign arrhythmias from clinically significant ones, potentially leading to false positives. Factors like motion artifact, poor signal quality, or rare arrhythmia patterns not well-represented in training data can influence its accuracy and lead to false negatives. While smartwatches are accurate for detecting atrial fibrillation, they still face hurdles like access to aging populations and trust in the medical community.
Physician oversight remains crucial, as AI-generated alerts are typically preliminary and require clinical review and confirmation with a diagnostic-grade ECG. The device usually integrates into clinical workflow by sending preliminary reports to the clinician for review, aiding in diagnosis and potential intervention. This allows for a more efficient process where physicians can correlate symptoms with heart rhythm data.

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

More from Verily Life Sciences

Study Watch
Verily Life Sciences
Cardiology AI
Verily Study Watch is a prescription-only, sensor-based wearable device for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform.
Study Watch with Irregular Pulse Monitor (Home)
Verily Life Sciences LLC
Cardiology AI
The Verily Study Watch with Irregular Pulse Monitor (Home) is a prescription-only wearable device for clinical research and healthcare use, designed to unobtrusively collect physiological data, including ECG and irregular pulse monitoring, with advanced sensors and cloud-based analytics.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.